Key result
Transseptal aspiration safely debulks thrombotic or infective mitral valve masses in high-risk nonsurgical patients.
Why the study?
Does transseptal aspiration using large-bore catheters safely debulk mitral valve-adherent masses in high-risk nonsurgical patients?
Case Report (n=7)
Does transseptal aspiration using large-bore catheters safely debulk mitral valve-adherent masses in high-risk nonsurgical patients?
Transseptal aspiration of mitral valve-adherent masses using large-bore catheters is technically feasible and safe as a bailout approach in high-risk, nonsurgical patients.
Answers are grounded in this paper and cite their sources.
May expand percutaneous options for high-risk nonsurgical mitral mass patients; hypothesis-generating and requires prospective trials.
BACKGROUND: Patients with thrombotic or infective masses on native or biological mitral valve have no established treatment if deemed ineligible for surgery. This case series summarizes our initial experience with a transseptal interventional bailout approach. CASE SUMMARY: Seven high-risk patients (aged 74.0 ± 4.87 years; EuroSCORE II median 14.05%) underwent transseptal debulking under cerebral protection. Six procedures used the INARI system (FlowTriever; INARI Medical) and the TriClip system (Abbott). Debulking was technically successful in all patients, without stroke, valve injury, or relevant mitral regurgitation. In 3 patients with severe mitral stenosis (gradient 23.0 ± 2.6 mm Hg), gradients were reduced by 16.6 ± 2.1 mm Hg. DISCUSSION: Transseptal aspiration using large-bore catheters appears feasible and safe in selected nonsurgical candidates with mitral valve-adherent masses. TAKE-HOME MESSAGES: Transseptal aspiration of left-sided mitral valve-adherent masses is technically feasible in high-risk nonsurgical patients using large-bore steerable catheters and a cerebral protection system. This series suggests that thrombotic or infective masses on the mitral valve can be safely debulked through transseptal aspiration.
No takes yet. Share an insight, caveat, or question.
Kücken et al. (2026) conducted a case report in Thrombotic or infective masses on native or biological mitral valve (n=7). Transseptal debulking/aspiration was evaluated on Technical success. Transseptal debulking of mitral valve-adherent masses was technically successful in 100% of high-risk nonsurgical patients (7/7), without stroke, valve injury, or relevant mitral regurgitation.
Synapse has enriched 10 related papers. Consider them for comparative context: